{
    "name": "Klippel-Trenaunay Syndrome",
    "slug": "klippel-trenaunay-syndrome",
    "aliases": [
        "KTS",
        "Angio-osteohypertrophy syndrome",
        "Klippel-Trenaunay-Weber Syndrome"
    ],
    "description": "Klippel-Trenaunay Syndrome (KTS) is a rare congenital vascular disorder characterized by the triad of port-wine stain (capillary malformation), varicose veins, and bony and soft tissue hypertrophy, typically affecting one or more limbs. The severity of symptoms varies widely among affected individuals. While the exact cause is unknown, it is thought to be due to sporadic genetic mutations occurring during embryonic development.",
    "category": "GENETIC",
    "icdCode": "Q74.3",
    "orphaCode": "488",
    "omimCode": "149000",
    "prevalence": "1 in 100,000",
    "estimatedCases": 3300,
    "ageOfOnset": "Congenital (at birth)",
    "inheritance": "SPORADIC",
    "symptoms": [
        "Port-wine stain (capillary malformation)",
        "Varicose veins",
        "Limb hypertrophy (overgrowth)",
        "Venous malformations",
        "Lymphatic malformations",
        "Arteriovenous malformations (rare)",
        "Pain",
        "Swelling",
        "Bleeding",
        "Cellulitis",
        "Deep vein thrombosis (DVT)",
        "Pulmonary embolism (PE)",
        "Discrepancy in limb length",
        "Macrodactyly (enlarged digits)"
    ],
    "affectedSystems": [
        "Vascular System",
        "Skeletal System",
        "Lymphatic System",
        "Integumentary System"
    ],
    "prognosis": "The prognosis varies depending on the severity of the symptoms and the complications that arise. Many individuals with KTS can lead relatively normal lives with appropriate management. However, some may experience significant disability and complications.",
    "lifeExpectancy": "Life expectancy is generally normal, but complications can reduce it.",
    "diagnosticMethods": [
        "Clinical examination",
        "Medical history",
        "Doppler ultrasound",
        "Magnetic resonance imaging (MRI)",
        "Computed tomography angiography (CTA)",
        "Venography",
        "Lymphoscintigraphy",
        "Genetic testing (limited utility, primarily for exclusion of other conditions)"
    ],
    "treatmentOptions": [
        {
            "name": "Compression therapy",
            "type": "SUPPORTIVE",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Sclerotherapy",
            "type": "SURGERY",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Laser therapy",
            "type": "THERAPY",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Surgery (e.g., vein stripping, epiphysiodesis)",
            "type": "SURGERY",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Pain management (analgesics)",
            "type": "MEDICATION",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Anticoagulation (e.g., heparin, warfarin, DOACs)",
            "type": "MEDICATION",
            "effectiveness": "MODERATELY_EFFECTIVE",
            "fdaApproved": true,
            "approvalYear": null
        },
        {
            "name": "Physical therapy",
            "type": "THERAPY",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Custom orthotics and prosthetics",
            "type": "SUPPORTIVE",
            "effectiveness": "SUPPORTIVE",
            "fdaApproved": false,
            "approvalYear": null
        },
        {
            "name": "Sirolimus (Rapamycin)",
            "type": "MEDICATION",
            "effectiveness": "EXPERIMENTAL",
            "fdaApproved": true,
            "approvalYear": 2009
        }
    ],
    "researchStatus": "ACTIVE_TRIALS",
    "clinicalTrialsCount": 15,
    "keyResearchCenters": [
        "Mayo Clinic",
        "Boston Children's Hospital",
        "Vascular Birthmarks Foundation",
        "National Institutes of Health (NIH)"
    ],
    "patientOrganizations": [
        {
            "name": "Vascular Birthmarks Foundation",
            "url": "https://www.birthmark.org/",
            "country": "USA"
        },
        {
            "name": "Klippel-Trenaunay Support Group",
            "url": "https://www.rareconnect.org/en/community/klippel-trenaunay-syndrome",
            "country": "International"
        }
    ],
    "relatedConditions": [
        "Parkes Weber Syndrome",
        "Sturge-Weber Syndrome",
        "Proteus Syndrome",
        "CLOVES Syndrome"
    ],
    "specialistTypes": [
        "Vascular Surgeon",
        "Dermatologist",
        "Orthopedic Surgeon",
        "Interventional Radiologist",
        "Hematologist",
        "Geneticist",
        "Physical Therapist"
    ],
    "eli5Summary": "Imagine some of your blood vessels and bones grew a little differently before you were born. This can cause a birthmark (like a wine stain), some bigger veins, and maybe one of your arms or legs is a bit bigger than the other. Doctors can help manage these things to make you feel better.",
    "clinicalSummary": "Klippel-Trenaunay Syndrome (KTS) is a rare congenital disorder characterized by the classic triad of capillary malformations (port-wine stains), venous varicosities, and limb hypertrophy. Lymphatic malformations are also frequently observed. The etiology is believed to involve sporadic mutations affecting vascular development. Diagnosis is primarily clinical, supported by imaging studies such as Doppler ultrasound, MRI, and venography. Management is largely symptomatic and may include compression therapy, sclerotherapy, laser therapy, surgical interventions, and pain management. Complications such as deep vein thrombosis, pulmonary embolism, and cellulitis require prompt treatment. Sirolimus is being investigated as a potential therapeutic agent. Genetic counseling is important to differentiate KTS from other related syndromes.",
    "historicalBackground": "Klippel-Trenaunay Syndrome was first described in 1900 by French physicians Maurice Klippel and Paul Tr√©naunay.",
    "recentBreakthroughs": [
        {
            "year": 2022,
            "title": "Sirolimus Shows Promise in Reducing Symptoms of Vascular Malformations",
            "description": "A study published in the *Journal of Vascular Anomalies* demonstrated that sirolimus (rapamycin) can significantly reduce the size and symptoms of vascular malformations in patients with KTS.",
            "sourceUrl": null
        },
        {
            "year": 2023,
            "title": "Genetic Mosaicism Investigated in Klippel-Trenaunay Syndrome",
            "description": "Research is ongoing to identify the specific genetic mutations responsible for KTS, with a focus on mosaic mutations that occur during embryonic development. This may lead to more targeted therapies in the future.",
            "sourceUrl": null
        }
    ],
    "heroImage": null,
    "diagrams": [],
    "lastUpdated": "2024-12-01",
    "reviewedBy": "MDRPedia Medical Team",
    "sources": [
        {
            "name": "Orphanet",
            "url": "https://www.orpha.net/consor/cgi-bin/Disease_Search.php?lng=EN&data_id=488"
        },
        {
            "name": "National Organization for Rare Disorders (NORD)",
            "url": "https://rarediseases.org/"
        },
        {
            "name": "Vascular Birthmarks Foundation",
            "url": "https://www.birthmark.org/"
        }
    ]
}